Introduction: Spermatic cord tumors represent 4% of scrotal tumors. The most common neoplasms are lipomas. Spermatic cord sarcomas (SCS) of the genitourinary tract account for 2% of all urological tumors. Herein we presented our experience in the treatment of these tumors and a review of the literature. Patients and Methods: A review of the literature was performed using the Medline database with no restriction on language and date of published papers. The literature search used the following terms: epidemiology, surgery, chemotherapy, radiotherapy and spermatic cord sarcomas. Four cases treated from December 2009 to May 2010 are described. Results: All patients were treated with radical orchiectomy. The final pathological report showed different types of sarcomas. Two of the patients were treated with adjuvant chemotherapy. 12 months after surgery, 2/4 patients were alive without signs of relapse. Conclusion: SCS are very rare tumors with a poor prognosis. SCS’s prognostic factors have been identified in grading, size, depth of invasion and surgical margin status. Age and performance status of the patient are however very important. Lymphatic and hematogenous dissemination is uncommon. Surgery is the most important treatment both in the first approach and in local relapse. The role of adjuvant chemotherapy and radiation therapy is still debated.

Keywords:
Orchiectomy, Paratesticular, Sarcoma, Spermatic cord
1.
Dangle P, Basavaraj DR, Bhattarai S, Paul AB, Biyani CS: Leiomyosarcoma of the spermatic cord: case report and literature review. Can Urol Assoc J 2007;1:55–58.
2.
Carrion Lopez P, Pastor Navarro H, Martinez Ruiz J, et al: Spermatic cord sarcomas: current status and report of four cases (in Spanish). Arch Esp Urol 2009;62:242–246.
3.
Rodriguez Toves LA, Estebanez Zarranz J, Camacho Parejo J, et al: Paratesticular lipoma (in Spanish). Actas Urol Esp 1997;21:620–622.
4.
Ballo MT, Zagars GK, Pisters PW, Feig BW, Patel SR, von Eschenbach AC: Spermatic cord sarcoma: outcome, patterns of failure and management. J Urol 2001;166:1306–1310.
5.
Russo P, Brady MS, Conlon K, et al: Adult urological sarcoma. J Urol 1992;147:1032–1036; discussion 1036–1037.
6.
Coleman J, Brennan MF, Alektiar K, Russo P: Adult spermatic cord sarcomas: management and results. Ann Surg Oncol 2003;10:669–675.
7.
Hinman F, Gibson TE: Tumors of the epididymis, spermatic cord and testicular tunics: a review of literature and report of three cases. Arch Surg 1924;8:100.
8.
Sogani PC, Grabstald H, Whitmore WF Jr: Spermatic cord sarcoma in adults. J Urol 1978;120:301–305.
9.
Gowing NF, Morgan AD: Paratesticular tumours of connective tissue and muscle. Br J Urol 1964;36(suppl):78–84.
10.
Soosay GN, Parkinson MC, Paradinas J, Fisher C: Paratesticular sarcomas revisited: a review of cases in the British Testicular Tumour Panel and Registry. Br J Urol 1996;77:143–146.
11.
Lewis JJ, Leung D, Woodruff JM, Brennan MF: Retroperitoneal soft-tissue sarcoma: analysis of 500 patients treated and followed at a single institution. Ann Surg 1998;228:355–365.
12.
Catton C, Jewett M, O’Sullivan B, Kandel R: Paratesticular sarcoma: failure patterns after definitive local therapy. J Urol 1999;161:1844–1847.
13.
Folpe AL, Weiss SW: Paratesticular soft tissue neoplasms. Semin Diagn Pathol 2000;17:307–318.
14.
Castineiras J, Varo C, Sanchez Bernal C, et al: Paratesticular neoplasms of mesenchymatous origin. Clinico-pathologic study (in Spanish). Actas Urol Esp 1995;19:40–45.
15.
Frates MC, Benson CB, Di Salvo DN, Brown DL, Laing FC, Doubilet PM: Solid extratesticular masses evaluated with sonography: pathologic correlation. Radiology 1997;204:43–46.
16.
Kishore B, Khare P, Gupta RJ, Gupta C, Khare V: A rare case of paratesticular pleomorphic rhabdomyosarcoma diagnosed by fine needle aspiration: a case report. Diagn Cytopathol 2010;38:121–126.
17.
Lopes RI, Leite KR, Lopes RN: Paratesticular leiomyosarcoma treated by enucleation. Int Braz J Urol 2006;32:66–67.
18.
Heslin MJ, Woodruff J, Brennan MF: Prognostic significance of a positive microscopic margin in high-risk extremity soft tissue sarcoma: implications for management. J Clin Oncol 1996;14:473–478.
19.
Collin CF, Friedrich C, Godbold J, Hajdu S, Brennan MF: Prognostic factors for local recurrence and survival in patients with localized extremity soft-tissue sarcoma. Semin Surg Oncol 1988;4:30–37.
20.
Lewis JJ, Leung D, Casper ES, Woodruff J, Hajdu SI, Brennan MF: Multifactorial analysis of long-term follow-up (more than 5 years) of primary extremity sarcoma. Arch Surg 1999;134:190–194.
21.
Pisters PW, Leung DH, Woodruff J, Shi W, Brennan MF: Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol 1996;14:1679–1689.
22.
Beech DJ, Pollock RE: Surgical management of primary soft tissue sarcoma. Hematol Oncol Clin North Am 1995;9:707–718.
23.
Sclama AO, Berger BW, Cherry JM, Young JD Jr: Malignant fibrous histiocytoma of the spermatic cord: the role of retroperitoneal lymphadenectomy in management. J Urol 1983;130:577–579.
24.
Vorstman B, Block NL, Politano VA: The management of spermatic cord liposarcomas. J Urol 1984;131:66–69.
25.
Grey LF, Sorial RF, Shaw WH: Spermatic cord sarcoma. Leiomyosarcoma and retroperitoneal lymph node dissection. Urology 1986;27:28–31.
26.
Catton CN, Cummings BJ, Fornasier V, O’Sullivan B, Quirt I, Warr D: Adult paratesticular sarcomas: a review of 21 cases. J Urol 1991;146:342–345.
27.
Khoubehi B, Mishra V, Ali M, Motiwala H, Karim O: Adult paratesticular tumours. BJU Int 2002;90:707–715.
28.
Torosian MH, Wein AJ: Liposarcoma of the spermatic cord: case report and review of the literature. J Surg Oncol 1987;34:179–181.
29.
Hermans BP, Foster RS, Bihrle R, et al: Is retroperitoneal lymph node dissection necessary for adult paratesticular rhabdomyosarcoma? J Urol 1998;160:2074–2077.
30.
Schwartz SL, Swierzewski SJ, Sondak VK, Grossman HB: Liposarcoma of the spermatic cord: report of 6 cases and review of the literature. J Urol 1995;153:154–157.
31.
Grosfeld JL, Weber TR, Weetman RM, Baehner RL: Rhabdomyosarcoma in childhood: analysis of survival in 98 cases. J Pediatr Surg 1983;18:141–146.
32.
Blitzer PH, Dosoretz DE, Proppe KH, Shipley WU: Treatment of malignant tumors of the spermatic cord: a study of 10 cases and a review of the literature. J Urol 1981;126:611–614.
33.
Pisters PW, Harrison LB, Leung DH, Woodruff JM, Casper ES, Brennan MF: Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J Clin Oncol 1996;14:859–868.
34.
Dotan ZA, Tal R, Golijanin D, et al: Adult genitourinary sarcoma: the 25-year Memorial Sloan-Kettering experience. J Urol 2006;176:2033–2038; discussion 2038–2039.
35.
Mondaini N, Palli D, Saieva C, et al: Clinical characteristics and overall survival in genitourinary sarcomas treated with curative intent: a multicenter study. Eur Urol 2005;47:468–473.
36.
Goodman FR, Staunton MD, Rees HC: Liposarcoma of the spermatic cord. J R Soc Med 1991;84:499–500.
37.
Cruz Guerra NA, Linares Quevedo A, Cuesta Roca C, Clemente Ramos L, Briones Mardones G, Maganto Pavon E: Spermatic cord liposarcoma: report of a new case (in Spanish). Arch Esp Urol 2002;55:191–193.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.